Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

FAHD AL-SAGHIR

Allopathic & Osteopathic Physicians Internal Medicine Nephrology

NPI
1073584223
CMS profile
320518
Location
PONTIAC, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$4,310.55

54 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

FAHD AL-SAGHIR

NPI 1073584223 · CMS profile ID 320518

Allopathic & Osteopathic Physicians / Internal Medicine / Nephrology

PONTIAC, MI

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073584223?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
FAHD AL-SAGHIR, NPI 1073584223, CMS profile ID 320518. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073584223?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). FAHD AL-SAGHIR, NPI 1073584223, CMS profile ID 320518. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073584223?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
FAHD AL-SAGHIR, NPI 1073584223, CMS profile ID 320518, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 2; records 51–54 of 54 matching records. This page contains 4 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1073584223?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

54 matching records · $4,310.55 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 54 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–54 of 54.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
GlaxoSmithKline, LLC. $11.0501/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 801954351 CMS
AstraZeneca Pharmaceuticals LP $19.5101/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 829903037 CMS
Vifor Pharma, Inc. $19.3901/21/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816085795 CMS
Vifor Pharma, Inc. $17.6401/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 816084669 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $10,376.13 60
PY2020 $7,798.10 37
PY2021 $4,310.55 54
PY2022 $1,793.32 63
PY2023 $968.58 48
PY2024 $3,876.42 56
PY2025 $2,769.61 59

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $3,266,326.48 71
PY2024 Recipient $88,967.00 1
PY2024 Principal investigator $101,717.10 22
PY2023 Principal investigator $7,157.70 8
PY2022 Principal investigator $70,257.63 55
PY2021 Principal investigator $140,543.76 40
PY2020 Principal investigator $154,461.96 46
PY2019 Principal investigator $84,124.78 37

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

71 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CSL Behring $26,930.00 12/29/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665432
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $3,049.90 12/23/2025 Non-covered Recipient Entity
Elixia MKC LLC
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220815101
Principal investigator 1 Boehringer Ingelheim International GmbH $139.92 12/17/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634951
Principal investigator 1 Boehringer Ingelheim International GmbH $359.64 12/17/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634953
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 12/17/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634955
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $47.71 12/17/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220792921
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $6,559.00 12/10/2025 Non-covered Recipient Entity
Elixia MKC LLC
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220815099
Principal investigator 1 CSL Behring $600.00 12/05/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665426
Principal investigator 1 CSL Behring $675.00 12/05/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665428
Principal investigator 1 CSL Behring $8,220.00 12/05/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665430
Principal investigator 1 Boehringer Ingelheim International GmbH $11.66 11/19/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634947
Principal investigator 1 Boehringer Ingelheim International GmbH $19.98 11/19/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634949
Principal investigator 1 CSL Behring $26,317.00 11/17/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665424
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $47.41 11/12/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220792919
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $4,250.00 11/11/2025 Non-covered Recipient Entity
Elixia MKC LLC
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220815097
Principal investigator 1 CSL Behring $34,457.00 10/29/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665422
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $25.84 10/21/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220792917
Principal investigator 1 CSL Behring $2,000.00 10/13/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665420
Principal investigator 1 CSL Behring $1,082.31 10/09/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665464
Principal investigator 1 CSL Behring $600.00 10/06/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665416
Principal investigator 1 CSL Behring $1,925.00 10/06/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665418
Principal investigator 1 CSL Behring $19,459.00 09/17/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665414
Principal investigator 1 CSL Behring $175.65 09/08/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665462
Principal investigator 1 CSL Behring $500.00 09/03/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665412
Principal investigator 1 CSL Behring $1,425.00 08/29/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665410
Principal investigator 1 Boehringer Ingelheim International GmbH $58.30 08/26/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634941
Principal investigator 1 Boehringer Ingelheim International GmbH $159.84 08/26/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634943
Principal investigator 1 Boehringer Ingelheim International GmbH $36.50 08/26/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634945
Principal investigator 1 CSL Behring $735.15 08/25/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665460
Principal investigator 1 CSL Behring $13,027.00 08/20/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665408
Principal investigator 1 Boehringer Ingelheim Pharmaceuticals, Inc. $12,000.00 08/07/2025 Non-covered Recipient Entity
Elixia MKC LLC
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220815095
Principal investigator 1 CSL Behring $16.71 08/06/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665458
Principal investigator 1 Boehringer Ingelheim International GmbH $70.32 08/01/2025 Non-covered Recipient Entity
Michigan Kidney Consultants PC-Pontiac
A simultaneous vs. staggered initiation study of BI 690517 and empagliflozin for SGLT2i treatment-naive participants with CKD No dispute reported 06/30/2026 1220634939
Principal investigator 1 CSL Behring $45,100.00 07/16/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665406
Principal investigator 1 CSL Behring $600.00 07/07/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665402
Principal investigator 1 CSL Behring $1,350.00 07/07/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665404
Principal investigator 1 CSL Behring $7,101.00 06/30/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665400
Principal investigator 1 CSL Behring $514.53 06/30/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665456
Principal investigator 1 CSL Behring $34,791.00 06/30/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673980
Principal investigator 1 CSL Behring $750.00 06/23/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665398
Principal investigator 2 CSL Behring $494,776.50 06/18/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673978
Principal investigator 2 CSL Behring $456,262.00 05/28/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673974
Principal investigator 1 CSL Behring $11,537.00 05/14/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665396
Principal investigator 1 CSL Behring $514.53 05/12/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665454
Principal investigator 1 CSL Behring $194.61 05/05/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665452
Principal investigator 2 CSL Behring $441,162.00 04/29/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673786
Principal investigator 1 CSL Behring $30.26 04/25/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665450
Principal investigator 1 AstraZeneca Pharmaceuticals LP $10,636.80 04/23/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185541924
Principal investigator 1 CSL Behring $389.61 04/23/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665448
Principal investigator 1 AstraZeneca Pharmaceuticals LP $5,200.00 04/16/2025 Non-covered Recipient Entity
TEXAS ARTHRITIS CENTER, PA
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185541926
Principal investigator 1 CSL Behring $17,564.00 04/16/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665394
Principal investigator 1 CSL Behring $16.71 04/11/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665446
Principal investigator 1 CSL Behring $16.71 04/10/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665444
Principal investigator 1 CSL Behring $600.00 04/09/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665392
Principal investigator 1 CSL Behring $423.76 04/07/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665442
Principal investigator 1 CSL Behring $10,952.00 03/19/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665390
Principal investigator 1 Eli Lilly and Company $1,723.04 03/18/2025 Non-covered Recipient Entity
ELIXIA COVID-19 LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187879219
Principal investigator 1 CSL Behring $665.92 03/17/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665440
Principal investigator 2 CSL Behring $430,840.00 03/17/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673990
Principal investigator 1 CSL Behring $544.25 02/21/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665438
Principal investigator 1 CSL Behring $375,603.00 02/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673988
Principal investigator 1 CSL Behring $9,331.00 02/19/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665388
Principal investigator 1 CSL Behring $157.28 02/19/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665436
Principal investigator 1 AstraZeneca Pharmaceuticals LP $4,350.00 01/29/2025 Non-covered Recipient Entity
ELIXIA
A Phase III, Randomised, Multicentre, Double-blind Study to Evaluate the Efficacy, Safety and Tolerability of Zibotentan/Dapagliflozin FDC Compared to Dapagliflozin Alone in Participants with Chronic Kidney Disease and High Proteinuria No dispute reported 06/30/2026 1185541928
Principal investigator 1 CSL Behring $1,437.83 01/23/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665434
Principal investigator 1 Eli Lilly and Company $203,530.00 01/21/2025 Non-covered Recipient Entity
ELIXIA MKC LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187879221
Principal investigator 3 CSL Behring $245,027.00 01/20/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252673986
Principal investigator 1 CSL Behring $2,579.00 01/10/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665384
Principal investigator 1 CSL Behring $4,734.00 01/10/2025 Non-covered Recipient Entity
Elixia MKC
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252665386
Principal investigator 1 AstraZeneca Pharmaceuticals LP $46,386.80 01/03/2025 Non-covered Recipient Entity
ELIXIA
a phase 3,randomised,double blind,active controlled study to assess the efficacy,safety and tolerability of baxdrostat in combination with dapagliflozin compared with dapagliflozin alone on chronic kidney disease ckd progression in participants with ckd and high blood pressure No dispute reported 06/30/2026 1185541922
Principal investigator 3 CSL Behring $233,917.00 01/03/2025 Non-covered Recipient Entity
Total Renal Research Inc.
A Phase 2b/3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Combined Dose-Finding and Cardiovascular Outcome Study to Investigate the Efficacy and Safety of CSL300 (Clazakizumab) in Subjects With End Stage Kidney Disease Undergoing Dialysis No dispute reported 06/30/2026 1252674186